Monitor AX-0811 target engagement data in early January 2027 as the first clinical catalyst from the AI-enabled pipeline. The activist stake (SC 13D/A) adds overhang — watch for any escalation or strategic demands from Van Herk Investments.
Price Chart
Executive Summary
ProQR announced the appointment of Chris Hart (ex-Eli Lilly VP of Data Science) as Chief Data and AI Officer and Thomas Wolf (Hugging Face co-founder/CSO) as a strategic AI advisor to the Board. The hires support ProQR's strategy to scale AI across its Axiomer RNA editing platform. The company expects up to 5 clinical data readouts over the next 12 months, with AX-0811 target engagement data due in early January 2027. The filing is routine personnel news with no financial data, but the cross-filing context of a recent SC 13D/A activist stake adds mild pressure.
Key Facts
- Chris Hart, PhD, appointed Chief Data and AI Officer; previously VP of Data Science and AI/ML at Eli Lilly.
- Thomas Wolf, PhD (Hugging Face co-founder/CSO), joins Board as strategic AI advisor.
- AX-0811, first AI-discovered program, in clinical testing; target engagement data expected early January 2027.
- Company expects up to 5 clinical data readouts over the next 12 months across 4 development programs.
- AX-0811 achieved ~60% editing efficiency in humanized models, ~6x higher than prior generation AX-0810.
- Discovery timelines reduced from ~3 years to ~3 months using AI-enabled discovery.
- Cross-filing context: SC 13D/A filed by Van Herk Investments B.V. on June 30, 2026 (activist stake).
Financial Impact
No financial figures disclosed; personnel appointments with no immediate revenue or cost impact.
Risk Factors
- Preclinical/early clinical data may not predict future results; AX-0811 data is binary catalyst risk.
- Activist stake (SC 13D/A) could lead to board pressure or strategic changes.
- Integration and execution of AI strategy may not deliver expected pipeline acceleration.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-109819 |
| Document: tm2625923d1_6k.htm | 0001104659-26-109819 |
| Document: 0001104659-26-109819-index-headers.html | 0001104659-26-109819 |
| Document: 0001104659-26-109819-index.html | 0001104659-26-109819 |
| Document: 0001104659-26-109819.txt | 0001104659-26-109819 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 6-K | $1.70 $1.66 | ▼ −2.35% | ▼ −1.68% | $1.23 (−27.94%) |
Sep 9, 2026 6w ago | 6-K | $1.99 $1.86 | ▼ −6.53% | ▼ −5.44% | $1.23 (−38.44%) |
Jul 16, 2026 14w ago | EFFECT | $1.67 $1.79 | ▼ −7.19% | ▼ −8.86% | $1.23 (+26.65%) |
Jun 25, 2026 17w ago | 6-K | $1.53 $1.81 | ▼ −18.30% | ▼ −16.13% | $1.23 (+19.93%) |
Jun 25, 2026 17w ago | 424B5 | $1.53 $1.81 | ▲ +18.30% | ▲ +16.13% | $1.23 (−19.93%) |
Jun 2, 2026 20w ago | 6-K | $1.47 $1.41 | ▼ −4.08% | ▼ −0.26% | $1.23 (−16.67%) |
May 12, 2026 24w ago | 6-K | $1.60 $1.51 | ▲ +5.63% | ▲ +5.70% | $1.23 (+23.44%) |
Apr 30, 2026 25w ago | 6-K | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.23 (−21.97%) |
Apr 30, 2026 25w ago | Press Release | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.23 (−21.97%) |
Apr 8, 2026 28w ago | 6-K | $1.98 $1.95 | ▼ −1.52% | ▼ −4.70% | $1.23 (−38.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers